PT-141 (Bremelanotide)
Not vascular. Central. The desire pathway — activated.
30-day full guarantee. Notice a difference or it's free — no return required.
Mechanism
Step 01
MC4R Agonism
PT-141 (Bremelanotide) is a cyclic heptapeptide that binds melanocortin 4 receptors (MC4R) in the hypothalamus. MC4R activation is directly linked to sexual arousal and motivation in both men and women — not arousal downstream of blood flow, but the desire signal itself. This is a fundamentally different point of intervention than every PDE5 inhibitor (Viagra, Cialis) on the market. Those compounds manage the symptom. PT-141 addresses the origin.
Step 02
Central vs. Peripheral
PDE5 inhibitors work peripherally — they inhibit the enzyme that breaks down cGMP in smooth muscle, increasing blood flow. They require baseline arousal to work and don't address hypoactive desire. PT-141 bypasses this entirely: MC4R agonism initiates the arousal cascade in the CNS. For patients where PDE5 inhibitors fail — typically those with hypoactive sexual desire disorder (HSDD) rather than pure vascular ED — PT-141 is the mechanism that actually addresses the problem.
Step 03
Both-Sex Efficacy
MC4R pathways are present and functionally equivalent in men and women. The RECONNECT Phase III trial was conducted in premenopausal women with HSDD — the compound earned its FDA basis in female populations. Male studies show equivalent MC4R activation and arousal response. Unlike every other compound in this space, PT-141 was built to work equally across both sexes because the hypothalamic mechanism doesn't differentiate.
The Evidence
These findings describe peer-reviewed research on PT-141 (Bremelanotide) — the active compound in Peak Libido. Claims are about the compound, not our formulation.
Simon et al. · Obstetrics & Gynecology 2019 · RECONNECT Phase III RCT
"In the RECONNECT Phase III trial (N=1,247 premenopausal women with hypoactive sexual desire disorder), Bremelanotide (PT-141) demonstrated a statistically significant 72% response rate in the primary endpoint — satisfying sexual events per month — versus 37% in placebo. The compound subsequently received FDA approval under the trade name Vyleesi."
The RECONNECT trial was the basis for FDA approval of Bremelanotide for HSDD in August 2019. PT-141 is one of only two FDA-approved compounds specifically for female sexual dysfunction — the other being Flibanserin (Addyi). PT-141 showed superior tolerability in head-to-head comparison.
Diamond et al. · Journal of Sexual Medicine 2006 · PT-141 Male Studies
"PT-141 produced significant increases in erectile function scores in men with mild-to-moderate erectile dysfunction. Critically, PT-141 demonstrated efficacy in PDE5-inhibitor non-responders — patients for whom sildenafil had failed — confirming that the melanocortin pathway operates independently of the NO/cGMP pathway targeted by PDE5 inhibitors."
PT-141's efficacy in PDE5 non-responders is the most clinically significant finding: it confirms a distinct mechanism of action. Men for whom Viagra doesn't work aren't facing a vascular problem — they're facing a desire-pathway deficit that PT-141 addresses directly.
The Product
Your Peak Libido pen, a 30-day supply of single-use needle tips, and bacteriostatic water for reconstitution — one discreet, unbranded box.
Questions
No — completely different mechanism. Viagra and Cialis (PDE5 inhibitors) work peripherally: they increase blood flow by inhibiting the enzyme that breaks down cGMP in smooth muscle. They require sexual arousal to work and they don't address low desire. PT-141 works centrally — it activates melanocortin receptors in the hypothalamus, initiating the desire cascade in the brain. It's the difference between treating a symptom (insufficient blood flow) and addressing the origin (insufficient desire signal).
Yes — the primary clinical trial (RECONNECT) was conducted in women, not men. The FDA approval of Bremelanotide (the branded version of PT-141) was specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. MC4R pathways are equivalent in men and women. PT-141 is one of the only compounds in this space with primary clinical data from female populations.
Onset is 45–120 minutes from subcutaneous administration. First use can be on the slower end of that window. The effect typically lasts 6–12 hours. Unlike PDE5 inhibitors which require arousal to initiate effect, PT-141's central mechanism means you'll notice the desire shift before any physical response — that's the mechanism working as designed.
The most commonly reported side effect in the RECONNECT trial was transient nausea — occurring in approximately 40% of participants and typically resolving within 2 hours without intervention. Flushing (facial warmth) and mild headache were also reported. Starting at the lower 0.75mg dose on first use reduces the incidence of nausea significantly. No serious adverse events were attributed to PT-141 in the Phase III data.
30-day full refund, no return required. PT-141 is typically effective on the first or second use — it's not a compound that requires weeks of accumulation. If you don't notice an effect within your first 3–4 administrations over 30 days, we return your $299. We compound at the dosing levels used in the trial.
Ships as lyophilised powder in a sterile vial. Reconstitute with bacteriostatic water using a fresh syringe and needle. Administer via subcutaneous injection — the lower abdomen or flank is the most common site. Rotate injection sites session to session. Ships stable at ambient temperature; refrigerate on arrival and use reconstituted solution within 21–28 days.
Standard workplace and roadside drug screens test for recreational substances and common medications — peptides will not appear on these screens. If you compete in a WADA-sanctioned sport, verify the current prohibited list at wada-ama.org before use, as regulations update annually. We recommend confirming with your sport's governing body before any sanctioned competition.
